Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 19.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,025,357 shares of the oil and gas company’s stock after buying an additional 323,357 shares during the period. Core Laboratories N.V. accounts for about 1.8% of Kayne Anderson Rudnick Investment Management LLC’s investment portfolio, making the stock its 12th biggest holding. Kayne Anderson Rudnick Investment Management LLC owned approximately 4.59% of Core Laboratories N.V. worth $199,904,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of CLB. Parallel Advisors LLC lifted its holdings in Core Laboratories N.V. by 13.1% during the second quarter. Parallel Advisors LLC now owns 1,008 shares of the oil and gas company’s stock worth $101,000 after buying an additional 117 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Core Laboratories N.V. by 63.7% during the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after buying an additional 439 shares during the period. Shine Investment Advisory Services Inc. purchased a new stake in Core Laboratories N.V. during the second quarter worth $134,000. Advisory Services Network LLC lifted its holdings in Core Laboratories N.V. by 33.3% during the second quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock worth $138,000 after buying an additional 341 shares during the period. Finally, First Bank & Trust lifted its holdings in Core Laboratories N.V. by 5.8% during the second quarter. First Bank & Trust now owns 1,493 shares of the oil and gas company’s stock worth $152,000 after buying an additional 82 shares during the period.

Core Laboratories N.V. (NYSE:CLB) traded down $2.96 during midday trading on Wednesday, hitting $101.34. The company had a trading volume of 558,500 shares, compared to its average volume of 558,552. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.81 and a current ratio of 2.18. Core Laboratories N.V. has a 52-week low of $86.55 and a 52-week high of $125.83. The firm has a market cap of $4,604.57, a P/E ratio of 56.99 and a beta of 1.57.

Core Laboratories N.V. (NYSE:CLB) last released its earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.04. Core Laboratories N.V. had a return on equity of 52.89% and a net margin of 12.06%. The firm had revenue of $166.20 million for the quarter, compared to the consensus estimate of $160.94 million. During the same period in the prior year, the firm earned $0.38 EPS. The firm’s revenue was up 1.4% on a year-over-year basis. sell-side analysts predict that Core Laboratories N.V. will post 1.99 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 21st. Investors of record on Friday, October 20th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.17%. The ex-dividend date is Thursday, October 19th. Core Laboratories N.V.’s payout ratio is 126.44%.

Several analysts have recently commented on the company. BidaskClub lowered Core Laboratories N.V. from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. ValuEngine upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Morgan Stanley decreased their price objective on Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, August 7th. Finally, Deutsche Bank AG assumed coverage on Core Laboratories N.V. in a report on Tuesday, October 10th. They set a “buy” rating and a $109.00 price objective for the company. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $108.64.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/kayne-anderson-rudnick-investment-management-llc-has-199-90-million-holdings-in-core-laboratories-n-v-clb/1705363.html.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.